Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
16.1 ^USD	+15.83%		+39.39%	+206.08%

May. 07	Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating	MT
May. 06	Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M	MT

Stoke Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022

March 06, 2023 at 07:00 am EST

Stoke Therapeutics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported sales was USD 3.27 million. Net loss was USD 25.66 million compared to USD 24.45 million a year ago. Basic loss per share from continuing operations was USD 0.65 compared to USD 0.66 a year ago.
For the full year, sales was USD 12.41 million. Net loss was USD 101.07 million compared to USD 85.81 million a year ago. Basic loss per share from continuing operations was USD 2.6 compared to USD 2.34 a year ago.

Latest news about Stoke Therapeutics, Inc.

Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating	May. 07	MT
Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M	May. 06	MT
Stoke Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Stoke Therapeutics Appoints Thomas Leggett CFO	Apr. 29	MT
Stoke Therapeutics, Inc. Announces Executive Changes, Effective May 7, 2024	Apr. 29	CI
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer	Apr. 17	CI
Sector Update: Health Care Stocks Advance Premarket Thursday	Mar. 28	MT
Stoke Therapeutics Prices Upsized $125 Million Share Offering	Mar. 28	MT
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Stoke Therapeutics Plans $75 Million Public Offering	Mar. 26	MT
Sector Update: Health Care Stocks Advance Late Afternoon	Mar. 26	MT
Stoke Therapeutics Rises After Investigational Drug Shows Improvement in Dravet Syndrome Patients	Mar. 26	MT
Top Midday Gainers	Mar. 26	MT
JPMorgan Adjusts Price Target on Stoke Therapeutics to $13 From $6, Maintains Neutral Rating	Mar. 26	MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	Mar. 26	MT
Needham Adjusts Stoke Therapeutics' Price Target to $22 From $14, Maintains Buy Rating	Mar. 26	MT
Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $21 From $18, Keeps Buy Rating	Mar. 26	MT
US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings	Mar. 26	MT
Top Premarket Gainers	Mar. 26	MT
Wedbush Adjusts Stoke Therapeutics' Price Target to $17 From $13, Keeps Outperform Rating	Mar. 26	MT
Canaccord Genuity Adjusts Stoke Therapeutics Price Target to $21 From $18, Maintains Buy Rating	Mar. 26	MT
TD Cowen Upgrades Stoke Therapeutics to Outperform From Market Perform	Mar. 26	MT
North American Morning Briefing : Markets Steady as Traders Eye Next Inflation Gauge	Mar. 26	DJ
Stoke Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Stoke Therapeutics, Inc Announces New Data that Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome	Mar. 25	CI

Chart Stoke Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Companyâs initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Sector

Biotechnology & Medical Research

Calendar

2024-06-04 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Stoke Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.1 USD

Average target price

22.14 USD

Spread / Average Target

+37.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
STOKE THERAPEUTICS, INC.	+206.08%	839M
MODERNA, INC.	+41.79%	54.04B
LONZA GROUP AG	+47.13%	41.96B
IQVIA HOLDINGS INC.	-0.56%	41.92B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B

Other Biotechnology & Medical Research